Beta 2 receptor action leading to hyperglycemia/hypoglycemia is mediated by which of the following enzymes?

Explanation

## Correct Answer: A. Adenylyl cyclase Beta-2 adrenergic receptors are G-protein coupled receptors (specifically Gs-coupled) that mediate metabolic effects including hyperglycemia. When epinephrine or norepinephrine binds to β2 receptors, the activated Gs protein directly stimulates **adenylyl cyclase**, which catalyzes the conversion of ATP to cyclic AMP (cAMP). This increased intracellular cAMP activates protein kinase A (PKA), which phosphorylates and activates hormone-sensitive lipase and glycogen phosphorylase, leading to glycogenolysis and lipolysis. In the pancreas, β2 stimulation inhibits insulin secretion (via cAMP-mediated mechanisms), contributing to hyperglycemia. Conversely, β2 blockade (as with non-selective beta-blockers like propranolol) can mask hypoglycemia symptoms and impair glucose recovery in diabetic patients—a critical safety concern in Indian clinical practice where beta-blockers are widely used for hypertension and cardiac disease. The adenylyl cyclase–cAMP–PKA axis is the canonical β2-mediated signaling pathway for all metabolic effects, making it the discriminating answer. ## Why the other options are wrong **B. Phospholipase C** — Phospholipase C is the downstream effector of **Gq-coupled receptors** (e.g., α1-adrenergic, muscarinic M1/M3, angiotensin II receptors), not β2 receptors. PLC generates IP3 and DAG, mediating calcium mobilization and PKC activation—mechanisms unrelated to β2-mediated glucose metabolism. This is a common trap confusing different G-protein signaling pathways. **C. Guanylyl cyclase** — Guanylyl cyclase produces cyclic GMP (cGMP) and is activated by **nitric oxide and natriuretic peptides**, not adrenergic receptors. While cGMP has vasodilatory effects, it plays no role in β2-mediated hyperglycemia or glucose homeostasis. This option exploits confusion between different second-messenger systems. **D. Phospholipase A2** — Phospholipase A2 releases arachidonic acid from membrane phospholipids, leading to eicosanoid synthesis (prostaglandins, leukotrienes). While some adrenergic effects involve PLA2, it is **not the primary mediator** of β2-induced hyperglycemia. The cAMP pathway is the canonical and rate-limiting mechanism for metabolic effects. ## High-Yield Facts - **β2 receptors → Gs-coupled → adenylyl cyclase → ↑cAMP → PKA activation** is the canonical pathway for hyperglycemia and metabolic effects. - **Non-selective beta-blockers (propranolol, atenolol)** block β2-mediated cAMP production, masking hypoglycemia symptoms and impairing glucose recovery in Indian diabetic patients on insulin/sulfonylureas. - **β2 stimulation in pancreatic islets** inhibits insulin secretion via cAMP-PKA, directly contributing to hyperglycemia independent of hepatic glycogenolysis. - **Adenylyl cyclase is the rate-limiting enzyme** in β2 signaling; its inhibition by Gi-coupled receptors (α2, M2, adenosine A1) explains counter-regulatory effects on glucose metabolism. - **Selective β2 agonists** (salbutamol, terbutaline) can cause transient hyperglycemia in Indian asthma/COPD patients due to adenylyl cyclase activation and reduced insulin secretion. ## Mnemonics **Gs → cAMP → Hyperglycemia** **G**s-coupled β2 → **A**denylyl cyclase → c**AMP** → **P**rotein kinase **A** → Glycogenolysis + ↓Insulin = **Hyperglycemia**. Use when recalling β2 metabolic effects. **Beta-Blocker Trap in Diabetes** **Non-selective beta-blockers block β2 → ↓cAMP → ↓glucose recovery + masked hypoglycemia symptoms.** Selective β1-blockers (metoprolol, atenolol at low doses) are safer in Indian diabetic patients. Remember: propranolol = danger in diabetes. ## NBE Trap NBE pairs β2 receptors with multiple second-messenger enzymes (PLC, guanylyl cyclase, PLA2) to exploit confusion between Gs, Gq, and other G-protein pathways. Students who memorize "adrenergic = multiple pathways" without anchoring to the **primary Gs-cAMP axis** fall for distractors. ## Clinical Pearl In Indian clinical practice, a diabetic patient on insulin presenting with recurrent hypoglycemic episodes may be masked by propranolol (non-selective beta-blocker), delaying recognition and recovery. Switching to a selective β1-blocker (e.g., metoprolol) restores the ability to sense and counter hypoglycemia via β2-mediated cAMP-driven glucose mobilization—a critical safety adjustment in our high-burden diabetes population. _Reference: Guyton & Hall Physiology Ch. 61 (Adrenergic Receptors); KD Tripathi Pharmacology Ch. 10 (Adrenergic Agonists & Antagonists); Harrison Principles of Internal Medicine Ch. 72 (Catecholamines & Sympathomimetic Drugs)_